Want to see DYN full AI Analyst Report?
DYN Stock Chart & Stats
$24.44
$0.55(2.30%)
At close: 4:00 PM EDT
$24.44
$0.55(2.30%)
Day’s Range― - ―
52-Week Range$11.17 - $27.13
Previous CloseN/A
Volume5.07M
Average Volume (3M)2.58M
Market Cap
$4.95B
Enterprise Value$3.01K
Total Cash (Recent Filing)$898.48M
Total Debt (Recent Filing)$19.87M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Oct 29, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding186,746,430
10 Day Avg. Volume3,130,021
30 Day Avg. Volume2,584,936
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.27Price Target Upside64.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary FORCE Delivery PlatformDyne’s FORCE platform provides a durable technical moat by enabling targeted delivery to muscle and related tissues. Platform-level delivery differentiates multiple candidates, supports pipeline expansion across neuromuscular indications, and underpins repeatable partnerships and licensing revenue opportunities.
Regulatory Progress For DYNE-251 (Priority Review)Priority Review of the DYNE-251 BLA is a structural de-risking step: potential approval would shift Dyne from pre-commercial to commercial-stage, create an initial revenue stream, validate the platform clinically, and materially change capital needs and partnership dynamics over the next 2–6 months and beyond.
Extended Runway From FinancingThe sizable equity raise combined with a Hercules tranche materially extends operational runway, reducing near-term financing pressure. This allows the company to advance registrational programs, pursue launches or additional trials, and increases the probability of hitting key milestones without immediate cash-driven disruption.
Bears Say
High Cash Burn And Sustained LossesDyne remains pre-revenue with very large, persistent cash burn, meaning continued reliance on external financing. Over time this forces management to prioritize programs by capital efficiency, raises execution risk if funding gaps occur, and limits margin visibility until commercial sales emerge.
Erosion Of Shareholders' EquityMaterial declines in equity reflect accumulated losses and dilution, reducing the company’s capital buffer. Lower equity constrains balance-sheet flexibility, increases dependence on external capital, and can amplify the shareholder impact of future financings or disappointing clinical outcomes.
Debt Secured Against Company Assets Including IPThe amended Hercules facility provides flexibility but pledges substantial assets, including IP, as collateral. This restricts strategic options, can complicate future licensing or M&A, and creates creditor priority over core assets if covenants are tested, elevating structural financing risk.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics, Inc.’s price range in the past 12 months?
Dyne Therapeutics, Inc. lowest stock price was $11.17 and its highest was $27.13 in the past 12 months.
What is Dyne Therapeutics, Inc.’s market cap?
Dyne Therapeutics, Inc.’s market cap is $4.95B.
When is Dyne Therapeutics, Inc.’s upcoming earnings report date?
Dyne Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Dyne Therapeutics, Inc.’s earnings last quarter?
Dyne Therapeutics, Inc. released its earnings results on Jul 29, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.749 by -$0.331.
Is Dyne Therapeutics, Inc. overvalued?
According to Wall Street analysts Dyne Therapeutics, Inc.’s price is currently Undervalued.
Does Dyne Therapeutics, Inc. pay dividends?
Dyne Therapeutics, Inc. does not currently pay dividends.
What is Dyne Therapeutics, Inc.’s EPS estimate?
Dyne Therapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Dyne Therapeutics, Inc. have?
Dyne Therapeutics, Inc. has 186,746,430 shares outstanding.
What happened to Dyne Therapeutics, Inc.’s price movement after its last earnings report?
Dyne Therapeutics, Inc. reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.749. Following the earnings report the stock price went up 2.51%.
Which hedge fund is a major shareholder of Dyne Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.27 (64.78% Upside)
$40.27 (64.78% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.35%
Trailing 12-Months
Company Description
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
DYN Stock 12 Month Forecast
Average Price Target
$40.27
▲(64.78% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
2.52% Insiders
25.88% Mutual Funds
1.70% Other Institutional Investors
56.16% Public Companies and
Individual Investors